AGTC - Applied Genetic and TeamedOn ink licensing deal for gene therapy development

Applied Genetic Technologies ([[AGTC]] -0.6%) and gene therapy company TeamedOn International have signed a licensing agreement to advance gene therapy to treat X-linked retinoschisis ((XLRS)), an inherited disease that causes loss of vision due to degeneration of the retina in males.Under the terms of the agreement, Applied Genetic will provide TeamedOn with the clinical trial material, pre-clinical and clinical data generated for the development of the company’s investigational intravitreal gene therapy candidate, rAAV2tYF-CB-hRS1.Applied Genetic discontinued its XLRS clinical program and development of rAAV2tYF-CB-hRS1 in 2018 because defined efficacy endpoints were not met using intravitreal injection.TeamedOn will now conduct all activities required to reinitiate clinical development of the program, with Applied Genetic being eligible to receive milestones and royalties based on clinical progress.

For further details see:

Applied Genetic and TeamedOn ink licensing deal for gene therapy development